Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2013 Sep 5

PMID 24000979

Citations 27

Authors

Bernadette Marrero

Shawna Shirley

Richard Heller

Affiliations

Soon will be listed here.

Abstract

Electroporation (EP) is a method used to physically deliver therapeutic molecules such as plasmid DNA directly to tissues. It has been used safely and successfully in clinical studies and preclinical cancer models to deliver genes to a variety of tissues. In cancer research cytokine therapy is emerging as a promising tool that can be used to boost the host response to tumor antigens. The delivery of cytokines as recombinant proteins can result in toxicity and other adverse effects; however the delivery of cytokine genes using EP has been shown to be safe and effective. Interleukin 15 (IL-15) is a cytokine that promotes the innate as well as the adaptive immune response to cancer cells and bacterial pathogens. In this study we used EP to deliver a human IL-15 plasmid (phIL-15) directly to tumors to examine its anti-cancer effects. B16.F10 melanoma tumors were induced in C57BL/6J mice and phIL-15 was delivered three times over the course of a week. Expression of the transgene, tumor volume, long-term survival and resistance to challenge were monitored in these animals. Delivery of IL-15 plasmid by EP resulted in increased IL-15 expression within the tumor compared to the injection only control. This expression peaked at 12 to 18 hours after the first delivery and was sustained at lower levels after the second and third deliveries. The delivery of the phIL-15 resulted in tumor regression, long-term survival and greater protection against tumor recurrence when cancer cells were reintroduced compared to control plasmid. From these results we can conclude that the delivery of IL-15 plasmid to tumors using EP is a promising avenue to investigate for its anti-tumor effects, however more work needs to be done to increase the stability of the gene once it is delivered and to elucidate the anti-tumor mechanism.

Citing Articles

Nano-Pulse Treatment Overcomes the Immunosuppressive Tumor Microenvironment to Elicit In Situ Vaccination Protection against Breast Cancer.

Nanajian A, Scott M, Burcus N, Ruedlinger B, Oshin E, Beebe S Vaccines (Basel). 2024; 12(6).

PMID: 38932362 PMC: 11209453. DOI: 10.3390/vaccines12060633.

Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.

Reschke R, Enk A, Hassel J Int J Mol Sci. 2024; 25(12).

PMID: 38928238 PMC: 11203481. DOI: 10.3390/ijms25126532.

Impact of Physical Exercise on Melanoma Hallmarks: Current Status of Preclinical and Clinical Research.

Ceci C, Garcia-Chico C, Atzori M, Lacal P, Lista S, Santos-Lozano A J Cancer. 2024; 15(1):1-19.

PMID: 38164270 PMC: 10751671. DOI: 10.7150/jca.88559.

Biomaterial-based gene therapy.

Yu Y, Gao Y, He L, Fang B, Ge W, Yang P MedComm (2020). 2023; 4(3):e259.

PMID: 37284583 PMC: 10239531. DOI: 10.1002/mco2.259.

Acute Effects of Intratumor DNA Electrotransfer.

Bhandary M, Sales Conniff A, Miranda K, Heller L Pharmaceutics. 2022; 14(10).

PMID: 36297532 PMC: 9611921. DOI: 10.3390/pharmaceutics14102097.

References

Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy M, Le T . Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine. 2002; 20(3):121-9. DOI: 10.1006/cyto.2002.1989. View

Heller L, Coppola D . Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther. 2002; 9(19):1321-5. DOI: 10.1038/sj.gt.3301802. View

Kirkwood J, Moschos S, Wang W . Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006; 12(7 Pt 2):2331s-2336s. DOI: 10.1158/1078-0432.CCR-05-2538. View

Stonier S, Schluns K . Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett. 2009; 127(2):85-92. PMC: 2808451. DOI: 10.1016/j.imlet.2009.09.009. View

Tagaya Y, Bamford R, DeFilippis A, Waldmann T . IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996; 4(4):329-36. DOI: 10.1016/s1074-7613(00)80246-0. View

Heller L, Heller R . Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther. 2010; 10(4):312-7. DOI: 10.2174/156652310791823489. View

Peng B, Zhao Y, Xu L, Xu Y . Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine. 2007; 25(11):2064-73. DOI: 10.1016/j.vaccine.2006.11.042. View

Heller L, Heller R . In vivo electroporation for gene therapy. Hum Gene Ther. 2006; 17(9):890-7. DOI: 10.1089/hum.2006.17.890. View

Haass N, Smalley K, Li L, Herlyn M . Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005; 18(3):150-9. DOI: 10.1111/j.1600-0749.2005.00235.x. View

10.

Yu W, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H . IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol. 1997; 62(4):450-7. DOI: 10.1002/jlb.62.4.450. View

11.

Grabstein K, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V . Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994; 264(5161):965-8. DOI: 10.1126/science.8178155. View

12.

Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, Murakami K . Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Anticancer Res. 2007; 27(4B):2305-10. View

13.

Heller L, Cruz Y, Ferraro B, Yang H, Heller R . Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16.F10 mouse melanomas. Cancer Gene Ther. 2010; 17(12):864-71. PMC: 2981654. DOI: 10.1038/cgt.2010.43. View

14.

Lucas M, Heller L, Coppola D, Heller R . IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002; 5(6):668-75. DOI: 10.1006/mthe.2002.0601. View

15.

Budagian V, Bulanova E, Paus R, Bulfone-Paus S . IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006; 17(4):259-80. DOI: 10.1016/j.cytogfr.2006.05.001. View

16.

Castillo E, Schluns K . Regulating the immune system via IL-15 transpresentation. Cytokine. 2012; 59(3):479-90. PMC: 3422378. DOI: 10.1016/j.cyto.2012.06.017. View

17.

Tomayko M, Reynolds C . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-54. DOI: 10.1007/BF00300234. View

18.

Carson W, Giri J, Lindemann M, Linett M, Ahdieh M, Paxton R . Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994; 180(4):1395-403. PMC: 2191697. DOI: 10.1084/jem.180.4.1395. View

19.

Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg A . Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev. 2002; 12(3):155-64. DOI: 10.1089/108729002760220752. View

20.

Wang Y, Li D, Shi H, Wen Y, Yang L, Xu N . Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res. 2009; 15(22):6901-11. DOI: 10.1158/1078-0432.CCR-09-0484. View